A Phase 1 Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies
Phase of Trial: Phase I/II
Latest Information Update: 27 Oct 2018
At a glance
- Drugs AB-928 (Primary) ; GLS 010 (Primary)
- Indications Cancer
- Focus Adverse reactions
- Sponsors Arcus Biosciences
- 10 Aug 2018 Status changed from planning to recruiting.
- 09 May 2018 According to an Arcus Biosciences media release, company has submitted regulatory filing to initiate this trial and expect to initiate dosing in patients in mid-2018.
- 17 Apr 2018 According to an Arcus Biosciences media release, data from dose-escalation portion is expected in the first half of 2019.